Argireline (Acetyl Hexapeptide-3)

Also known as: Acetyl hexapeptide-3, Acetyl hexapeptide-8

Argireline (acetyl hexapeptide-3/8) is a synthetic peptide designed to mimic the N-terminal domain of SNAP-25, a component of the SNARE complex essential for vesicle fusion. By competitively binding to the SNARE complex, it partially inhibits the release of acetylcholine at the neuromuscular junction, thereby reducing muscle contraction intensity. This mechanism is analogous to botulinum toxin but is milder and reversible, leading to a temporary softening of dynamic facial wrinkles, particularly periorbital and forehead expression lines. Despite its widespread use in topical cosmetic formulations, peer-reviewed research on Argireline remains limited. No indexed PubMed studies directly investigate its efficacy or safety in human subjects. Available data derive primarily from in vitro models and unpublished industry reports, which suggest a dose-dependent reduction in neurotransmitter release. However, the translational relevance of these findings to intact human skin is uncertain, as peptide penetration through the stratum corneum is a known limitation. Clinically, Argireline is marketed as a non-invasive alternative to botulinum toxin for reducing expression lines, but its experimental status precludes definitive conclusions about efficacy or long-term safety. Regulatory approval for cosmetic use does not require the same evidence standards as therapeutic agents. Without peer-reviewed clinical trials, its mechanism remains theoretically plausible but unsubstantiated in vivo. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides